New combo aims to fight Hard-to-Treat colorectal cancer
NCT ID NCT03657641
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This study combines two drugs—regorafenib (a chemotherapy pill) and pembrolizumab (an immunotherapy)—to treat metastatic colorectal cancer that has spread and not responded to earlier treatments. The trial has two phases: first to find the safest dose, then to see if the combo helps people live longer without their cancer growing. It involves 73 adults who have already tried standard chemotherapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
regorafenib and pembrolizumab
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 73 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and it may not improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.